A Phase 1 interventional study of Gabapentin and Diphenhydramine in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-07.
Sponsored by Pfizer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Human experimental pain models are useful in understanding the mechanisms underlying clinical pain conditions and can be used to test the analgesic efficacy of drugs used in the management of pain. Once established these models can be used as mechanism biomarkers in early development clinical studies to establish proof of mechanism for novel compounds. The cold pain model is a mechanistic pain biomarker with potential application in proof of mechanism studies. In this study we aim to set up this cold pain model at a Clinical Research Unit and demonstrate we can effectively screen subjects for this model and examine the effect of morphine, diphenhydramine, and gabapentin in the cold pain model.
Cold pain methodology development
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gabapentin
Drug: Diphenhydramine
Drug: Morphine
Drug: Placebo
Capsule, single 1200mg dose
Tablet, single 50mg dose
IV, single 10mg dose
Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
Average Pain (0-120 Seconds): Cold Pain Test Visual Analog Scale (VAS)
Area under the cold pain test Visual Analog Scale (VAS) time curve (AUCcpt 0 to 120 seconds \[sec\]) averaged over the 120 sec for each time point assessed. Participant adjusted 100 millimeter (mm) electronic VAS with range of "no pain" (0) to "maximum pain" (100) at the anchor endpoints of the scale and "moderate pain" at the midpoint. Pain reported while non-dominant hand was placed in thermostatically controlled water bath at 2±1°C for a maximum of 120 sec.
Time frame: Pre-dose, 1, 1.5, 2, 4, and 8 hours post-dose
Interpolated Average Pain (0-8 Hours)
Interpolated average pain (0 to 8 hours): area under the curve (AUC) of average pain (0 to 120 seconds) recorded at each of the time points taken over 8 hour time period divided by 8.
Time frame: Pre-dose to 8 hours post-dose
Number of Participants With Clinically Significant Findings in Vital Signs
Supine blood pressure measured to nearest millimeter of mercury (mmHg), pulse rate measured with automated device or manually in the brachial/radial artery for at least 30 seconds.
Time frame: Predose, Day 1, Day 2 each treatment period, follow-up visit (at least 7 days after last dosing)
Number of Participants With Clinically Significant Abnormal Findings on Physical Examination
Full physical examination consisting of an examination of the abdomen, cardiovascular systems, lungs, lymph nodes, mouth, musculoskeletal and neurological systems, skin, extremities, head, ears, eyes, nose, throat and thyroid gland.
Time frame: Pre-dose and follow-up visit (at least 7 days after last dosing)
Number of Participants With Abnormal Findings on Electrocardiogram (ECG)
Standard 12-lead ECG performed after subject had rested quietly for at least 10 minutes in a supine position.
Time frame: Pre-dose and follow-up visit (at least 7 days after last dosing)
Number of Participants With Abnormal Haematology, Clinical Chemistry, Urinalysis Results
Standard haematology, clinical chemistry, and urinalysis safety laboratory tests.
Time frame: Pre-dose, follow-up visit (at least 7 days after last dosing)
Number of Participants With Abnormal Cardiac Monitoring Results
Continuous cardiac monitoring during intervenous (IV) infusion dosing (morphine or placebo).
Time frame: Pre-dose through duration of IV infusion dosing
Number of Participants With Abnormal Pulse Oxymetry Results
Pulse oxymetry to monitor percentage of hemoglobin saturated with oxygen during intervenous (IV) infusion dosing (morphine or placebo).
Time frame: Predose through duration of IV infusion dosing
| Milestone | Placebo, Morphine, Diphenhydramine, Gabapentin | Morphine, Gabapentin, Placebo, Diphenhydramine | Gabapentin, Diphenhydramine, Morphine, Placebo | Diphenhydramine, Placebo, Gabapentin, Morphine |
|---|---|---|---|---|
| Started | 5 | 5 | 5 | 4 |
| Completed | 5 | 5 | 5 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
Area under the cold pain test Visual Analog Scale (VAS) time curve (AUCcpt 0 to 120 seconds \[sec\]) averaged over the 120 sec for each time point assessed. Participant adjusted 100 millimeter (mm) electronic VAS with range of "no pain" (0) to "maximum pain" (100) at the anchor endpoints of the scale and "moderate pain" at the midpoint. Pain reported while non-dominant hand was placed in thermostatically controlled water bath at 2±1°C for a maximum of 120 sec.
| mm | Gabapentin | Morphine | Diphenhydramine | Placebo |
|---|---|---|---|---|
| Pre-dose | 45.2 ± 16.15 | 45.5 ± 16.10 | 45.0 ± 16.66 | 44.9 ± 15.16 |
| 1 hour | 41.9 ± 16.95 | 28.6 ± 16.88 | 45.1 ± 17.29 | 38.4 ± 15.69 |
| 1.5 hours | 39.4 ± 16.21 | 26.1 ± 18.28 | 42.3 ± 16.67 | 40.2 ± 17.75 |
| 2 hours | 40.4 ± 17.71 | 25.6 ± 18.44 | 40.5 ± 17.22 | 39.5 ± 16.86 |
| 4 hours | 41.9 ± 16.37 | 34.7 ± 18.29 | 44.2 ± 17.35 | 44.3 ± 16.70 |
| 8 hours | 44.7 ± 15.06 | 36.7 ± 17.14 | 43.8 ± 15.08 | 44.2 ± 14.55 |
Interpolated average pain (0 to 8 hours): area under the curve (AUC) of average pain (0 to 120 seconds) recorded at each of the time points taken over 8 hour time period divided by 8.
| hours | Gabpentin | Morphine | Diphenhydramine | Placebo |
|---|---|---|---|---|
| Interpolated Average Pain (0-8 Hours) | 42.2 ± 3.67 | 33.4 ± 3.67 | 43.6 ± 3.67 | 42.8 ± 3.67 |
Supine blood pressure measured to nearest millimeter of mercury (mmHg), pulse rate measured with automated device or manually in the brachial/radial artery for at least 30 seconds.
No measurements were reported for this outcome.
Full physical examination consisting of an examination of the abdomen, cardiovascular systems, lungs, lymph nodes, mouth, musculoskeletal and neurological systems, skin, extremities, head, ears, eyes, nose, throat and thyroid gland.
No measurements were reported for this outcome.
Standard 12-lead ECG performed after subject had rested quietly for at least 10 minutes in a supine position.
No measurements were reported for this outcome.
Standard haematology, clinical chemistry, and urinalysis safety laboratory tests.
No measurements were reported for this outcome.
Continuous cardiac monitoring during intervenous (IV) infusion dosing (morphine or placebo).
No measurements were reported for this outcome.
Pulse oxymetry to monitor percentage of hemoglobin saturated with oxygen during intervenous (IV) infusion dosing (morphine or placebo).
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gabapentin | — | 0/19 (0%) | 9/19 (47.4%) |
| Morphine | — | 0/19 (0%) | 18/19 (94.7%) |
| Diphenhydramine | — | 0/19 (0%) | 5/19 (26.3%) |
| Placebo | — | 0/19 (0%) | 3/19 (15.8%) |
| Event | Gabapentin | Morphine | Diphenhydramine | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/19 | 7/19 | 0/19 | 0/19 |
| Feeling abnormalGeneral disorders | 2/19 | 7/19 | 0/19 | 0/19 |
| SomnolenceNervous system disorders | 6/19 | 7/19 | 5/19 | 1/19 |
| DizzinessNervous system disorders | 1/19 | 4/19 | 0/19 | 0/19 |
| ParaesthesiaNervous system disorders | 0/19 | 4/19 | 0/19 | 0/19 |
| Hot flushVascular disorders | 0/19 | 4/19 | 0/19 | 0/19 |
| Dry mouthGastrointestinal disorders | 0/19 | 3/19 | 0/19 | 0/19 |
| Chest painGeneral disorders | 0/19 | 3/19 | 0/19 | 0/19 |
| VomitingGastrointestinal disorders | 0/19 | 2/19 | 0/19 | 0/19 |
| FatigueGeneral disorders | 0/19 | 1/19 | 0/19 | 2/19 |
| Age, Categorical(Participants) | Entire Study Population |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 19 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 0 |
| Male | 19 |
The record gives a start of Jul 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gabapentin · Diphenhydramine · Morphine